Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 64135M105 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Prudential Financial Inc 13G | 11.2% |
10/7/2026
Event 9/30/2026
|
|
| Jennison Associates LLC 13G | 11.1% |
10/6/2026
Event 9/30/2026
|
|
|
Trails Edge Capital Partners, LP
13G/A
Amendment 1
|
4.5% |
8/14/2026
Event 6/30/2026
|
|
| Trails Edge Capital Partners, LP | 4.5% | ||
| Trails Edge Biotechnology Master Fund, LP | 4.5% | ||
| Ortav Yehudai | 4.5% | ||
|
Balyasny Asset Management L.P.
13G
|
5.2% |
8/14/2026
Event 6/30/2026
|
|
| Balyasny Asset Management L.P. | 5.2% | ||
| Bam GP LLC | 5.2% | ||
| Balyasny Asset Management Holdings LP | 5.2% | ||
| Dames GP LLC | 5.2% | ||
| Dmitry Balyasny | 5.2% | ||
|
Redmile Group, LLC
13G/A
Amendment 7
|
9.9% |
8/14/2026
Event 6/30/2026
|
|
| Redmile Group, LLC | 9.9% | ||
| Jeremy C. Green | 9.9% | ||
| Redmile Biopharma Investments I, L.P. | 5.1% | ||
|
Redmile Group, LLC
13G/A
Amendment 6
|
9.9%
Checked 5% or less
|
2/17/2026
Event 12/31/2025
|
|
| Redmile Group, LLC | 9.9% | ||
| Jeremy C. Green | 9.9% | ||
| Redmile Biopharma Investments I, L.P. | 4.8% | ||
|
Trails Edge Capital Partners, LP
13G
|
5.1% |
12/15/2025
Event 12/8/2025
|
|
| Trails Edge Capital Partners, LP | 5.1% | ||
| Trails Edge Biotechnology Master Fund, LP | 5.1% | ||
| Ortav Yehudai | 5.1% | ||
|
EcoR1 Capital, LLC
13G/A
Amendment 1
|
9.9% |
11/14/2025
Event 9/30/2025
|
|
| EcoR1 Capital, LLC | 9.9% | ||
| Oleg Nodelman | 9.9% | ||
| EcoR1 Capital Fund Qualified, L.P. | 8.6% | ||
|
Commodore Capital LP
13G/A
Amendment 1
|
3.0% |
8/14/2025
Event 6/30/2025
|
|
| Commodore Capital LP | 3.0% | ||
| Commodore Capital Master LP | 3.0% | ||
|
Baker Bros. Advisors LP
13G/A
Amendment 1
|
7.0% |
8/14/2025
Event 6/30/2025
|
|
| Baker Bros. Advisors LP | 7.0% | ||
| Baker Bros. Advisors (GP) LLC | 7.0% | ||
| Julian C. Baker | 7.0% | ||
| Felix J. Baker | 7.0% | ||
|
Baker Bros. Advisors LP
13G
|
10.0% |
5/15/2025
Event 3/31/2025
|
|
| Baker Bros. Advisors LP | 10.0% | ||
| Baker Bros. Advisors (GP) LLC | 10.0% | ||
| Julian C. Baker | 10.0% | ||
| Felix J. Baker | 10.0% | ||
|
FMR LLC
13G/A
Amendment 1
|
3.1% |
5/12/2025
Event 3/31/2025
|
|
| FMR LLC | 3.1% | ||
| Abigail P. Johnson | 3.1% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 6.8% |
4/23/2025
Event 3/31/2025
|
|
| Janus Henderson Group PLC 13G/A Amendment 2 | 0% |
2/14/2025
Event 12/31/2024
|
|
|
Great Point Partners, LLC
13G/A
Amendment 3
|
3.0% |
2/14/2025
Event 12/31/2024
|
|
| Great Point Partners, LLC | 3.0% | ||
| Dr. Jeffrey R. Jay, M.D. | 3.0% | ||
| Ms. Lillian Nordahl | 3.0% | ||
|
Redmile Group, LLC
13G/A
Amendment 5
|
9.9% |
2/14/2025
Event 12/31/2024
|
|
| Redmile Group, LLC | 9.9% | ||
| Jeremy C. Green | 9.9% | ||
| Redmile Biopharma Investments I, L.P. | 5.4% | ||
|
RTW Investments, LP
13G/A
Amendment 1
|
10.0% |
2/14/2025
Event 12/31/2024
|
|
| RTW Investments, LP | 10.0% | ||
| Roderick Wong, M.D. | 10.0% | ||
|
Casdin Capital, LLC
13G/A
Amendment 1
|
8.7% |
2/14/2025
Event 12/31/2024
|
|
| Casdin Capital, LLC | 8.7% | ||
| Casdin Partners Master Fund, L.P. | 7.2% | ||
| Casdin Partners GP, LLC | 7.2% | ||
| Eli Casdin | 8.7% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 865 | $24.1 k |
| 2026 Q2 | 115 | 17.3 M | $545 M |
| 2026 Q1 | 101 | 17.0 M | $342 M |
| 2025 Q4 | 94 | 16.5 M | $340 M |
| 2025 Q3 | 91 | 15.3 M | $265 M |
| 2025 Q2 | 88 | 16.1 M | $240 M |
| 2025 Q1 | 92 | 16.5 M | $193 M |
| 2024 Q4 | 96 | 16.1 M | $368 M |
| 2024 Q3 | 88 | 13.9 M | $581 M |
| 2024 Q2 | 70 | 13.7 M | $499 M |
| 2024 Q1 | 64 | 13.2 M | $670 M |
| 2023 Q4 | 39 | 9.65 M | $187 M |